GO:0034392 negative regulation of smooth muscle cell apoptotic process: Signaling Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034392 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of smooth muscle cell apoptosis.
• Hydrogen sulfide produced by vascular smooth muscle cells promotes plaque stability by activating TFEB-mediated autophagy, which blocks apoptosis.
• The paraspeckle protein NONO attenuates vascular calcification by inhibiting BMP2 transcription, thereby reducing osteogenic apoptosis of smooth muscle cells.
• Loss of Ncf1 in smooth muscle cells activates the STING pathway and exacerbates angiotensin II-induced aortic aneurysm and dissection, showing that Ncf1 normally restrains pro-apoptotic signaling.
• Reduced KCNMB1 expression drives vascular smooth muscle cell phenotypic switching and apoptosis, linking ion channel subunits to survival.
• Smad2 inhibition of MET transcription potentiates human vascular smooth muscle cell apoptosis, identifying a TGF-beta-Smad2-MET survival axis.
Description
Smooth muscle cells (SMCs) are contractile cells that line hollow organs and blood vessels, and their survival is essential for vascular and airway homeostasis. The Gene Ontology term GO:0034392, negative regulation of smooth muscle cell apoptotic process, captures all molecular events that suppress the programmed death of these cells. Apoptosis of SMCs is a double-edged sword: too little contributes to pathological remodeling and plaque instability, while too much drives aneurysm, calcification, and fibrosis. Understanding the negative regulators of SMC apoptosis is therefore central to cardiovascular, pulmonary, and gastrointestinal research. This article synthesizes QuickGO annotation and verified PubMed literature to explain the mechanisms, key genes, disease links, and experimental models used to study GO:0034392.
negative regulation of smooth muscle cell apoptotic process At A Glance
| GO ID | GO:0034392 |
|---|---|
| GO term | negative regulation of smooth muscle cell apoptotic process |
| Ontology | biological_process |
| Synonym | down regulation of smooth muscle cell apoptosis; inhibition of smooth muscle cell apoptosis; negative regulation of SMC apoptosis |
| Major function | Suppression of programmed cell death in smooth muscle cells |
| Related processes | Autophagy, TGF-beta signaling, STING pathway, ion channel regulation |
| Key regulators | TFEB, NONO, Ncf1, KCNMB1, Smad2, MET |
| Disease relevance | Atherosclerosis, aortic aneurysm, vascular calcification, pulmonary arterial hypertension |
What Is GO:0034392?
GO:0034392 is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of smooth muscle cell apoptotic process. It includes signaling cascades, transcriptional programs, and metabolic pathways that protect SMCs from programmed cell death. Synonyms include down regulation of smooth muscle cell apoptosis, inhibition of smooth muscle cell apoptosis, and negative regulation of SMC apoptosis.
Why Is negative regulation of smooth muscle cell apoptotic process Important in Cell Biology?
Dysregulation of SMC apoptosis underlies major human diseases. In atherosclerosis, SMC death promotes plaque instability and rupture, while in aortic aneurysm and dissection, excessive apoptosis weakens the vessel wall. In vascular calcification, osteogenic transition and apoptosis of SMCs drive mineral deposition. In pulmonary arterial hypertension, apoptosis resistance contributes to vascular remodeling. Thus, identifying negative regulators of SMC apoptosis offers therapeutic targets and biomarkers for cardiovascular and pulmonary diseases.
• Maintains vascular wall integrity by preventing excessive SMC loss.
• Promotes atherosclerotic plaque stability through autophagy-mediated survival.
• Limits vascular calcification by inhibiting osteogenic apoptosis.
• Prevents angiotensin II-induced aortic aneurysm and dissection.
• Regulates pulmonary arterial remodeling and hypertension.
• Influences phenotypic switching of SMCs in response to injury.
• Provides targets for therapies in fibrosis and idiopathic pulmonary fibrosis.
• Serves as a prognostic signature component in triple-negative breast cancer stroma.
• Links ion channel function to SMC survival.
• Connects TGF-beta signaling to MET-dependent survival.
What Happens During negative regulation of smooth muscle cell apoptotic process?
Initiation of survival signaling
In simple terms: Cells receive signals that tell them to stay alive.
Negative regulation of SMC apoptosis begins when extracellular or intracellular cues activate pro-survival pathways. For example, vascular SMC-derived hydrogen sulfide activates TFEB, which induces autophagy and protects against apoptosis. Similarly, NONO attenuates vascular calcification by inhibiting BMP2 transcription, reducing osteogenic apoptosis.
Autophagy and metabolic adaptation
In simple terms: Cells recycle their own components to survive stress.
Autophagy is a key survival mechanism. TFEB-mediated autophagy in SMCs promotes atherosclerotic plaque stability by preventing apoptosis. This pathway integrates metabolic stress signals to maintain SMC viability.
Inhibition of pro-apoptotic transcription
In simple terms: Survival signals block genes that would cause cell death.
NONO inhibits BMP2 transcription, reducing osteogenic differentiation and apoptosis of SMCs. Smad2 inhibition of MET transcription potentiates apoptosis, indicating that Smad2 normally suppresses apoptosis by maintaining MET expression.
Ion channel and redox regulation
In simple terms: Ion balance and oxidative stress control cell survival.
Reduced KCNMB1 expression leads to SMC phenotypic switch and apoptosis, showing that potassium channel subunits support survival. Ncf1 knockout activates the STING pathway and exacerbates aortic aneurysm, indicating that Ncf1-dependent redox regulation restrains pro-apoptotic inflammation.
Integration with disease-specific pathways
In simple terms: Survival signals are tuned to the disease context.
In pulmonary arterial remodeling, microRNAs modulate SMC apoptosis and proliferation. In idiopathic pulmonary fibrosis, network pharmacology and single-cell RNA sequencing reveal that Sanleng-Ezhu affects SMC apoptosis-related pathways. These context-specific regulators fine-tune the negative regulation of SMC apoptosis.
Key Genes Involved in GO:0034392 negative regulation of smooth muscle cell apoptotic process
The following genes and proteins have been experimentally linked to the negative regulation of smooth muscle cell apoptotic process.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TFEB | Transcription factor activating autophagy | Mediates H2S-induced SMC survival and plaque stability |
| NONO | Paraspeckle protein inhibiting BMP2 transcription | Attenuates vascular calcification and SMC apoptosis |
| Ncf1 | Regulatory subunit of NADPH oxidase | Knockout exacerbates aortic aneurysm via STING |
| KCNMB1 | Potassium channel subunit | Reduced expression causes SMC phenotypic switch and apoptosis |
| Smad2 | TGF-beta signaling effector | Inhibition potentiates SMC apoptosis via MET |
| MET | Receptor tyrosine kinase | Smad2-dependent transcription supports SMC survival |
| BMP2 | Bone morphogenetic protein | NONO inhibits its transcription to reduce calcification |
| STING | Innate immune adaptor | Activated by Ncf1 loss to promote apoptosis |
| H2S | Gasotransmitter | Promotes TFEB-mediated autophagy and survival |
| miRNAs | Post-transcriptional regulators | Modulate pulmonary arterial SMC apoptosis |
| Sanleng-Ezhu components | Herbal compounds | Affect SMC apoptosis pathways in IPF |
| Stromal signature genes | Prognostic markers | Include SMC apoptosis regulators in TNBC |
How Is negative regulation of smooth muscle cell apoptotic process Regulated?
The negative regulation of SMC apoptosis is controlled by a network of signaling pathways. TFEB-mediated autophagy is induced by hydrogen sulfide and promotes survival. NONO inhibits BMP2 transcription to prevent osteogenic apoptosis. Ncf1 suppresses STING activation, limiting pro-apoptotic inflammation. KCNMB1 maintains ion homeostasis and survival. Smad2 sustains MET expression to block apoptosis. These pathways are further modulated by microRNAs in pulmonary arterial remodeling and by herbal compounds in fibrosis models.
negative regulation of smooth muscle cell apoptotic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TFEB | Atherosclerosis | SMC-specific TFEB knockout or overexpression in ApoE-/- mice |
| Ncf1 | Aortic aneurysm and dissection | SMC-specific Ncf1 knockout in angiotensin II-infused mice |
| NONO | Vascular calcification | NONO knockout or overexpression in SMC cultures |
| KCNMB1 | Vascular remodeling | KCNMB1 knockdown in SMCs |
| Smad2 | SMC apoptosis | Smad2 inhibition in human SMCs |
Atherosclerosis and plaque stability
In atherosclerosis, SMC apoptosis contributes to plaque instability. Hydrogen sulfide produced by SMCs activates TFEB-mediated autophagy, which reduces apoptosis and promotes plaque stability. This identifies the H2S-TFEB axis as a potential therapeutic target.
Aortic aneurysm and dissection
Ncf1 knockout in SMCs exacerbates angiotensin II-induced aortic aneurysm and dissection by activating the STING pathway, leading to increased apoptosis. Thus, Ncf1 normally restrains pro-apoptotic signaling in the vessel wall.
Vascular calcification
NONO attenuates vascular calcification by inhibiting BMP2 transcription, reducing osteogenic differentiation and apoptosis of SMCs. Loss of NONO promotes calcification.
Pulmonary arterial hypertension and fibrosis
MicroRNAs regulate SMC apoptosis in pulmonary arterial remodeling. In idiopathic pulmonary fibrosis, Sanleng-Ezhu modulates SMC apoptosis-related pathways as revealed by network pharmacology and single-cell RNA sequencing.
From negative regulation of smooth muscle cell apoptotic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X protect SMCs from apoptosis? | SMC-specific knockout mouse |
| Does a point mutation in gene X alter survival? | Point-mutation knock-in mouse |
| Does overexpression of gene X reduce apoptosis? | SMC-specific overexpression mouse |
| Where is gene X expressed in SMCs? | Tagged knock-in reporter mouse |
| Does gene X regulate apoptosis in vitro? | CRISPR knockout in human SMC lines |
| Does gene X affect plaque stability? | ApoE-/- mouse with SMC-specific modification |
How to Study the negative regulation of smooth muscle cell apoptotic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| TUNEL | Apoptotic DNA fragmentation | SMC apoptosis in tissue sections |
| Annexin V flow cytometry | Phosphatidylserine externalization | Quantification of apoptosis in cultured SMCs |
| Western blot | Protein expression and phosphorylation | Autophagy and STING pathway activity |
| RNA-seq | Global transcriptome | Identification of survival pathways |
| ChIP-seq | Transcription factor binding | NONO and Smad2 target genes |
| Single-cell RNA-seq | Cell-type-specific expression | SMC heterogeneity in fibrosis and cancer |
| Network pharmacology | Compound-target-pathway networks | Herbal medicine mechanisms |
Apoptosis assays
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) and annexin V staining quantify SMC apoptosis in tissues and cultured cells.
Autophagy and signaling analysis
Western blotting for LC3, p62, and TFEB nuclear translocation assesses autophagy induction. STING pathway activation is measured by phospho-TBK1 and interferon-beta.
Transcriptional and epigenetic profiling
RNA-seq and ChIP-seq identify transcriptional changes and binding of factors such as NONO and Smad2.
Single-cell and network pharmacology
Single-cell RNA sequencing combined with network pharmacology reveals SMC apoptosis pathways in fibrosis and cancer.
How CRISPR Can Be Used to Study GO:0034392 negative regulation of smooth muscle cell apoptotic process
Knockout
CRISPR knockout of candidate genes such as Ncf1 or KCNMB1 in SMCs can test their role in apoptosis. Ncf1 knockout exacerbates aneurysm via STING, and KCNMB1 reduction promotes apoptosis.
Point Mutation
Point mutations can mimic disease-associated variants in genes like TFEB or Smad2 to assess effects on SMC survival.
Knock-in
Knock-in of tagged versions of NONO or TFEB allows tracking of their localization and interaction with apoptotic machinery.
Overexpression
Overexpression of protective genes such as TFEB or NONO in SMCs can reduce apoptosis and calcification in disease models.
How EDITGENE Supports negative regulation of smooth muscle cell apoptotic process Research
Researchers studying negative regulation of smooth muscle cell apoptotic process-related genes often need to determine whether a candidate gene is causally involved in SMC survival or is merely a bystander. EDITGENE provides CRISPR-based cell models and screening services to establish causality and mechanism.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of smooth muscle cell apoptotic process research.
Frequently Asked Questions About negative regulation of smooth muscle cell apoptotic process
What is GO:0034392?
GO:0034392 is the Gene Ontology term for negative regulation of smooth muscle cell apoptotic process, describing any process that stops or reduces apoptosis of smooth muscle cells.
What genes are involved in negative regulation of smooth muscle cell apoptosis?
Key genes include TFEB, NONO, Ncf1, KCNMB1, Smad2, and MET.
How does TFEB regulate smooth muscle cell apoptosis?
TFEB mediates autophagy induced by hydrogen sulfide, which protects SMCs from apoptosis and promotes plaque stability.
What is the role of NONO in vascular calcification?
NONO inhibits BMP2 transcription, reducing osteogenic differentiation and apoptosis of SMCs.
How does Ncf1 affect aortic aneurysm?
Ncf1 knockout in SMCs activates the STING pathway and exacerbates angiotensin II-induced aortic aneurysm and dissection.
What is the link between KCNMB1 and SMC apoptosis?
Reduced KCNMB1 expression leads to SMC phenotypic switch and apoptosis.
How does Smad2 regulate SMC survival?
Smad2 inhibition of MET transcription potentiates apoptosis, indicating Smad2 normally supports survival.
What diseases involve dysregulated SMC apoptosis?
Atherosclerosis, aortic aneurysm, vascular calcification, and pulmonary arterial hypertension.
What methods study negative regulation of SMC apoptosis?
TUNEL, annexin V, Western blot, RNA-seq, ChIP-seq, and single-cell RNA-seq.
How can CRISPR help study GO:0034392?
CRISPR knockout, point mutation, knock-in, and overexpression models can test causal roles of genes in SMC survival.
Conclusion
GO:0034392 encompasses critical protective mechanisms that maintain smooth muscle cell survival and vascular homeostasis. Key regulators such as TFEB, NONO, Ncf1, KCNMB1, and Smad2 have been experimentally linked to disease prevention. Understanding these pathways offers therapeutic opportunities for atherosclerosis, aneurysm, calcification, and pulmonary hypertension. EDITGENE provides comprehensive CRISPR services to accelerate this research.
References
- 1. Chen Z et al.. 2022. Vascular smooth muscle cell-derived hydrogen sulfide promotes atherosclerotic plaque stability via TFEB (transcription factor EB)-mediated autophagy.. Autophagy 18(10):2270-2287 PMID: 35090378
- 2. Lu Y et al.. 2024. Paraspeckle protein NONO attenuates vascular calcification by inhibiting bone morphogenetic protein 2 transcription.. Kidney Int 105(6):1221-1238 PMID: 38417578
- 3. Liu H et al.. 2024. Ncf1 knockout in smooth muscle cells exacerbates angiotensin II-induced aortic aneurysm and dissection by activating the STING pathway.. Cardiovasc Res 120(9):1081-1096 PMID: 38639325
- 4. Liu H et al.. 2025. Reduced expression of KCNMB1 leads to vascular smooth muscle cell phenotypic switch and apoptosis.. Biochem Pharmacol 241:117151 PMID: 40653026
- 5. Li F et al.. 2025. Construction of a stromal cell-related prognostic signature based on a 101-combination machine learning framework for predicting prognosis and immunotherapy response in triple-negative breast cancer.. Front Immunol 16:1544348 PMID: 40438115
- 6. Zhou X et al.. 2024. Deciphering the Underlying Mechanisms of Sanleng-Ezhu for the Treatment of Idiopathic Pulmonary Fibrosis Based on Network Pharmacology and Single-cell RNA Sequencing Data.. Curr Comput Aided Drug Des 20(6):888-910 PMID: 37559532
- 7. Grant JS et al.. 2013. MicroRNAs in pulmonary arterial remodeling.. Cell Mol Life Sci 70(23):4479-94 PMID: 23739951
- 8. Xie X et al.. 2021. Smad2 inhibition of MET transcription potentiates human vascular smooth muscle cell apoptosis.. Atheroscler Plus 44:31-42 PMID: 35445204
